STAT3 and B-cell non-Hodgkin lymphoma: Targeting STAT3 represents a promising strategy for the treatment of aggressive cancers displaying a constitutive activation of this pathway, including PEL, which is very aggressive B cell lymphoma KSHV-associated [23].